MariMed Reports Third Quarter 2026 Earnings
MARIMED INC. (MRMD) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 MariMed Reports Third Quarter 2026 Earnings NORWOOD, MA, November 11, 2026 - MariMed Inc. (“MariMed” or the “Company”) (CSE: MRMD) (OTCQB: MRMD), a leading multi-state cannabis operator focused on improving lives every day, today announced its financial results for t
How this was made
The 30-second read
Why it matters
The earnings release provides fresh financial metrics that were not publicly available before this filing.
Market read
First‑time disclosure of Q3 earnings for a micro‑cap cannabis firm; may trigger short‑term price movement.
What to watch
Potential regulatory delays on federal cannabis reform and 280E tax relief could dampen future growth.
Background
MariMed Inc. (CSE: MRMD, OTCQB: MRMD) is a multi‑state cannabis operator reporting its Q3 2026 results via an SEC Form 8‑K.
Ticker impact
MariMed Inc. filed its Q3 2026 earnings on Form 8‑K, reporting record quarterly revenue of $44.2 M and a GAAP loss of $3.5 M.
potential modest upside as investors price in record revenue and improved cash position
The company posted its highest quarterly revenue ever and positive operating cash flow, which are fresh, material data for a micro‑cap.
Market effects
Positive earnings may lift sentiment in the U.S. cannabis sector, highlighting demand growth.
Limited to Canadian and U.S. OTC markets where cannabis stocks trade.
Minimal; impact confined to niche cannabis investors.
Counterpoint
The company's reliance on wholesale pricing could compress margins, limiting upside.
Key entities
- companyMariMed Inc.
Cannabis operator reporting Q3 2026 earnings.
- executiveJon Levine
CEO of MariMed who commented on the results.